Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million

Bulletin Express07-07 17:25

Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD 1.15 million. The shares are intended for cancellation.

Including this latest transaction, Ascletis now holds 9.63 million repurchased shares pending cancellation, equivalent to approximately 0.91% of the company’s 1.06 billion issued shares (excluding treasury shares) as at the same date. The issued share count and treasury stock balance remain unchanged at 1,061.37 million and 7.08 million shares, respectively.

The repurchase forms part of a mandate approved on 29 June 2026 that authorises the company to buy back up to 106.14 million shares. Purchases executed under this mandate to date total 245,000 shares, representing 0.02% of the issued share base at the mandate approval date.

In accordance with Hong Kong listing rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128232538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128232538","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD 1.15 million. The shares are intended for cancellation.</p>\n<p>Including this latest transaction, Ascletis now holds 9.63 million repurchased shares pending cancellation, equivalent to approximately 0.91% of the company’s 1.06 billion issued shares (excluding treasury shares) as at the same date. The issued share count and treasury stock balance remain unchanged at 1,061.37 million and 7.08 million shares, respectively.</p>\n<p>The repurchase forms part of a mandate approved on 29 June 2026 that authorises the company to buy back up to 106.14 million shares. Purchases executed under this mandate to date total 245,000 shares, representing 0.02% of the issued share base at the mandate approval date.</p>\n<p>In accordance with Hong Kong listing rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Completes HKD 1.15 Million Buyback; Uncancelled Repurchased Shares Reach 9.63 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-07 17:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD 1.15 million. The shares are intended for cancellation.</p>\n<p>Including this latest transaction, Ascletis now holds 9.63 million repurchased shares pending cancellation, equivalent to approximately 0.91% of the company’s 1.06 billion issued shares (excluding treasury shares) as at the same date. The issued share count and treasury stock balance remain unchanged at 1,061.37 million and 7.08 million shares, respectively.</p>\n<p>The repurchase forms part of a mandate approved on 29 June 2026 that authorises the company to buy back up to 106.14 million shares. Purchases executed under this mandate to date total 245,000 shares, representing 0.02% of the issued share base at the mandate approval date.</p>\n<p>In accordance with Hong Kong listing rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1128232538","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128232538","pubTimestamp":1783416354,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药完成115万港元回购；未注销回购股份达963万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD 1.15 million. The shares are intended for cancellation.\nIncluding this latest transaction, Ascletis now holds 9.63 million repurchased shares pending cancellation, equivalent to approximately 0.91% of the company’s 1.06 billion issued shares (excluding treasury shares) as at the same date. The issued share count and treasury stock balance remain unchanged at 1,061.37 million and 7.08 million shares, respectively.\nThe repurchase forms part of a mandate approved on 29 June 2026 that authorises the company to buy back up to 106.14 million shares. Purchases executed under this mandate to date total 245,000 shares, representing 0.02% of the issued share base at the mandate approval date.\nIn accordance with Hong Kong listing rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128232538","isCrawlerRequest":true}